Services

Women’s Health

Targeted therapies have markedly changed the treatment and management of female tumors compared to conventional chemotherapy and radiotherapy. Patient selection for targeted therapies is dependent on the identification of tumor-associated biomarkers using advanced molecular techniques.

Breast and ovarian cancers are two of the most common cancers among women. Breast and ovarian cancers are clinically heterogeneous diseases with several recognized histological and molecular subtypes. Molecular profiling of breast and ovarian cancers is critical for patients’ treatment, management, and determining prognosis.

At Anwa, we offer different tests that help physicians and patients improve the outcome and management of breast and ovarian cancers, including PIK3CA, Anwa Breast Cancer Prognostic Profile, and Homologous Recombination Deficiency (HRD) profiling. Additionally, to identify patients at risk of developing breast and ovarian cancers, we offer BRCA1/2 testing using NGS technology.

Women’s Health

BRCA1/2 Sequencing

Anwa’s Breast Cancer Prognostic Profile is a multiparametric genetic assay based on the mRNA expression of 50 key breast cancer genes. This comprehensive prognostic assay allows for accurate molecular subtyping and offers oncologists vital insights into the disease progression.

BRCA1/2

15 working days

Blood sample

Women’s Health

PIK3CA Mutations

PIK3CA is the most commonly mutated gene in patients with HR+/HER2- advanced or metastatic breast cancer. Breast cancer patients with PIK3CA mutations may be eligible for Piqray (alpelisib) treatment.
At Anwa, we use an FDA-approved PCR test to detect 11 mutations in PIK3CA.

PIK3CA, 11 mutations

7 working days

Unstained FFPE slides

Women’s Health

Anwa Breast Cancer Prognostic Profile

Anwa’s Breast Cancer Prognostic Profile is a multiparametric genetic test based on the mRNA expression of 50 key breast cancer genes. This comprehensive prognostic profile allows for accurate molecular subtyping and offers oncologists vital insights about disease progression.

50 signature genes

10 working days

Unstained FFPE slides

Women’s Health

HRD profiling

Tumors that demonstrate homologous repair deficiency (HRD) are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). HRD Score testing and BRCA1/2 mutations testing have been approved for the selection of PARPi therapy. Our in-house HRD test combines multiplex and targeted deep sequencing of SNVs, InDels in whole coding regions and in the exon-intron boundaries of BRCA1 and BRCA2 genes along with the HRD Score based on over 24,000 SNPs.

24000 SNPs
+ BRCA1/2 genes

10 working days

Unstained FFPE slides